ADMA Biologics, Inc. (ADMA) return on equity (ROE)

Return on equity · fiscal 2025
30.8%

ADMA Biologics, Inc. (ADMA) earned a return on equity of 30.8% in fiscal 2025 (the year ended December 31, 2025). That is 25.9 percentage points lower than the 56.6% of fiscal 2024. Figures as of 17 Nov 2026, 21:04 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
30.8%
Change on fiscal 2024
−25.9 pts
Highest on record
56.6%fiscal 2024
Lowest on record
-2188.9%fiscal 2015
Fiscal years on record
142011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

ADMA Biologics, Inc. return on equity (ROE), in more detail

Across the 14 fiscal years on record (2011–2025), the highest was 56.6% in fiscal 2024 and the lowest -2188.9% in fiscal 2015. The fiscal 2025 figure is higher than in 92% of the 13 earlier fiscal years on record, whose median is -85.8%.

History · 14 fiscal years

Return on equity by fiscal year

ADMA Biologics, Inc. return on equity (ROE), year by year

ADMA Biologics, Inc. (ADMA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202530.8% 25.9 pts down
202456.6% 77.5 pts up
2023-20.9% 22.5 pts up
2022-43.4% 7.4 pts up
2021-50.8% 35.1 pts up
2020-85.8% 98.5 pts up
2019-184.3% 148.2 pts up
2018-332.5% 224.0 pts down
2017-108.5%—
2015-2188.9% 1909.0 pts down
2014-279.8% 207.8 pts down
2013-72.0% 5.5 pts up
2012-77.5% 1452.6 pts up
2011-1530.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on ADMA

ADMA Biologics, Inc., figure by figure

ADMA Biologics, Inc. (ADMA) overview: price, valuation and scorecard

ADMA Biologics, Inc. return on equity (ROE): questions and answers

What is ADMA Biologics, Inc.'s return on equity?

ADMA Biologics, Inc. (ADMA) earned a return on equity of 30.8% in fiscal 2025 (the year ended December 31, 2025). That is 25.9 percentage points lower than the 56.6% of fiscal 2024.

Is ADMA Biologics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 92% of the 13 earlier fiscal years on record, whose median is -85.8%.

What are the highest and lowest return on equity figures on record for ADMA Biologics, Inc.?

Across the 14 fiscal years on record (2011–2025), the highest was 56.6% in fiscal 2024 and the lowest -2188.9% in fiscal 2015.

How is ADMA Biologics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ADMA Biologics, Inc. (ADMA) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ADMA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.